Intra-Cellular Therapies, Inc.
Index- P/E- EPS (ttm)-3.32 Insider Own0.10% Shs Outstand94.52M Perf Week-0.42%
Market Cap4.62B Forward P/E- EPS next Y-1.67 Insider Trans-67.75% Shs Float92.23M Perf Month-4.21%
Income-298.00M PEG- EPS next Q-0.59 Inst Own94.50% Short Float / Ratio2.80% / 4.16 Perf Quarter3.96%
Sales188.10M P/S24.56 EPS this Y-8.40% Inst Trans1.91% Short Interest2.59M Perf Half Y-11.92%
Book/sh7.25 P/B6.59 EPS next Y41.80% ROA-40.40% Target Price69.62 Perf Year0.04%
Cash/sh6.50 P/C7.35 EPS next 5Y- ROE-45.50% 52W Range42.42 - 66.00 Perf YTD-9.77%
Dividend- P/FCF- EPS past 5Y-5.40% ROI-68.40% 52W High-27.65% Beta1.12
Dividend %- Quick Ratio9.50 Sales past 5Y202.50% Gross Margin91.40% 52W Low12.56% ATR1.82
Employees512 Current Ratio9.80 Sales Q/Q223.90% Oper. Margin- RSI (14)41.31 Volatility3.03% 3.89%
OptionableYes Debt/Eq0.00 EPS Q/Q40.10% Profit Margin- Rel Volume0.94 Prev Close48.77
ShortableYes LT Debt/Eq0.00 EarningsNov 03 BMO Payout- Avg Volume622.24K Price47.75
Recom1.80 SMA20-3.94% SMA50-6.65% SMA200-8.78% Volume583,384 Change-2.09%
Aug-22-22Downgrade Goldman Buy → Neutral $64 → $49
Jul-07-22Initiated Mizuho Buy $74
Jun-14-22Initiated UBS Buy $75
Apr-22-22Initiated Piper Sandler Neutral $59
Feb-16-22Initiated Goldman Buy $64
Sep-23-21Initiated Needham Buy $55
Dec-15-20Initiated BofA Securities Buy $40
Dec-10-20Initiated Goldman Buy $38
Feb-20-20Initiated Evercore ISI Outperform
Jan-31-20Downgrade JP Morgan Overweight → Neutral $26
Show Previous Ratings
Jan-03-23 08:00AM
Dec-22-22 10:53AM
Dec-20-22 10:48AM
Dec-14-22 08:44AM
09:32AM Loading…
Dec-12-22 09:32AM
Dec-08-22 08:00AM
Nov-30-22 10:28AM
Nov-26-22 09:00PM
Nov-23-22 09:55AM
Nov-18-22 01:38PM
Nov-10-22 08:00AM
Nov-07-22 09:55AM
Nov-05-22 09:20AM
08:55AM Loading…
Nov-03-22 08:55AM
Oct-27-22 08:00AM
Oct-17-22 10:43AM
Oct-06-22 07:09AM
Sep-16-22 04:30PM
Aug-09-22 08:45AM
Aug-02-22 08:00AM
Aug-01-22 10:01AM
Jul-07-22 09:40AM
Jun-21-22 02:33AM
Jun-13-22 08:00AM
May-29-22 08:38AM
05:34PM Loading…
May-12-22 05:34PM
May-11-22 03:55PM
May-10-22 06:24PM
May-09-22 05:15PM
May-03-22 08:00AM
May-02-22 03:00PM
Apr-25-22 07:00AM
Apr-21-22 08:00AM
Apr-06-22 10:07AM
Apr-05-22 08:00AM
Mar-20-22 08:45PM
Mar-14-22 06:31AM
Mar-09-22 09:11AM
Mar-01-22 08:55AM
Feb-28-22 08:38AM
Feb-22-22 08:00AM
Feb-17-22 03:02PM
Feb-10-22 08:00AM
Jan-28-22 07:09AM
Jan-24-22 03:27AM
Jan-10-22 05:38PM
Jan-07-22 04:01PM
Jan-04-22 10:05PM
Jan-03-22 04:01PM
Dec-27-21 11:38PM
Dec-24-21 09:15AM
Dec-23-21 10:32AM
Dec-21-21 09:18AM
Dec-20-21 08:59AM
Dec-14-21 06:56AM
Dec-08-21 07:38PM
Dec-06-21 04:01PM
Nov-09-21 02:00PM
Nov-02-21 08:00AM
Nov-01-21 03:01PM
Oct-26-21 10:26AM
Oct-19-21 07:30PM
Oct-18-21 08:00AM
Oct-08-21 08:00AM
Sep-28-21 09:28AM
Sep-27-21 09:19AM
Sep-22-21 08:00AM
Sep-21-21 01:21PM
Sep-20-21 07:30AM
Aug-16-21 08:52AM
Aug-13-21 04:48PM
Aug-10-21 08:00AM
Aug-09-21 06:00PM
Aug-02-21 03:01PM
Jun-19-21 02:44PM
Jun-15-21 01:04AM
Jun-07-21 08:00AM
May-26-21 08:00AM
May-10-21 03:00PM
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MARCUS JOEL SDirectorDec 19Sale50.825,000254,10029,233Dec 21 04:06 PM
Mates SharonChairman, President & CEODec 13Sale55.0033,0831,819,5651,100,309Dec 15 07:01 PM
Halstead MichaelEVP and General CounselDec 01Option Exercise15.4750,000773,50050,000Dec 02 07:14 PM
Halstead MichaelEVP and General CounselDec 01Sale53.7350,0002,686,5140Dec 02 07:14 PM
MARCUS JOEL SDirectorNov 07Sale52.3010,000523,02334,233Nov 08 04:12 PM
Hineline Lawrence J.SVP of Finance CFOSep 21Option Exercise15.4765,1641,008,08765,164Sep 23 09:01 PM
Hineline Lawrence J.SVP of Finance CFOSep 21Sale45.6365,1642,973,4060Sep 23 09:01 PM
VAN NOSTRAND ROBERT LDirectorAug 11Option Exercise12.6530,000379,50039,043Aug 12 06:09 PM
VAN NOSTRAND ROBERT LDirectorAug 11Sale57.1330,0001,713,9759,043Aug 12 06:09 PM
MARCUS JOEL SDirectorAug 11Sale59.2210,000592,20044,233Aug 12 06:05 PM
MARCUS JOEL SDirectorMay 12Sale55.0010,000550,00054,233May 13 05:24 PM
Neumann MarkEVP, Chief Commercial OfficerApr 08Option Exercise12.7386,3481,099,210131,687Apr 08 06:56 PM
Neumann MarkEVP, Chief Commercial OfficerApr 08Sale64.3786,3485,558,05145,339Apr 08 06:56 PM
RIGGS RORY BDirectorMar 18Sale61.1820,6371,262,5050Mar 18 08:12 PM
RIGGS RORY BDirectorMar 17Sale60.33141,4998,536,64620,637Mar 18 08:12 PM
RIGGS RORY BDirectorMar 16Sale59.2764,5343,824,827162,136Mar 18 08:12 PM
Mates SharonChairman, President & CEOMar 09Option Exercise2.8438,925110,5471,133,392Mar 10 04:13 PM
MARCUS JOEL SDirectorMar 08Sale52.6815,000790,15028,980Mar 09 09:49 PM
MARCUS JOEL SDirectorMar 07Sale54.525,000272,60043,980Mar 09 09:49 PM
Durgam Suresh K.Chief Medical OfficerMar 04Sale55.523,860214,30723,104Mar 04 06:05 PM
Durgam Suresh K.Chief Medical OfficerMar 02Sale56.984,177238,00526,964Mar 04 06:05 PM
Halstead MichaelEVP and General CounselFeb 24Sale51.987,906410,9330Feb 25 07:06 PM
Durgam Suresh K.Chief Medical OfficerFeb 24Sale52.274,046211,46831,141Feb 25 07:09 PM
Mates SharonChairman, President & CEOFeb 24Sale51.9822,5891,174,0741,094,467Feb 25 07:01 PM
Neumann MarkEVP, Chief Commercial OfficerFeb 24Sale52.217,906412,81045,339Feb 25 07:08 PM
Hineline Lawrence J.SVP of Finance CFOFeb 24Sale51.977,454387,3490Feb 25 07:04 PM
Durgam Suresh K.Chief Medical OfficerFeb 22Sale55.294,177230,95827,281Feb 23 07:08 PM
Neumann MarkEVP, Chief Commercial OfficerFeb 22Sale55.2911,139615,82745,339Feb 23 07:07 PM
Halstead MichaelEVP and General CounselFeb 22Sale55.4011,139617,1000Feb 23 07:05 PM
Hineline Lawrence J.SVP of Finance CFOFeb 22Sale55.4010,443578,5060Feb 23 07:02 PM
Mates SharonChairman, President & CEOFeb 22Sale55.3927,8471,542,4131,094,467Feb 23 07:00 PM